Tecen­triq pass­es neoad­ju­vant breast can­cer tri­al as Roche looks for ear­ly start on the next big check­point op­por­tu­ni­ty

Shot through hun­dreds of tri­als over the last decade, check­point in­hibitors have proven a ver­sa­tile tool. First ap­proved for melanoma, col­lec­tive­ly they now cov­er dozens of can­cer types and set­tings, earn­ing their de­vel­op­ers bil­lions in the process.

Large­ly, though, they have avoid­ed use in one of the most com­mon set­tings: Lo­cal­ized tu­mors typ­i­cal­ly treat­ed with ad­ju­vant or neo-ad­ju­vant ther­a­py. For drug com­pa­nies, Cowen es­ti­mat­ed last Oc­to­ber, it’s a po­ten­tial $110 bil­lion mar­ket, one they’re rapid­ly try­ing to fill. The firm not­ed a long list of tri­als were un­der­way and due to start read­ing out — for breast can­cer at least —  this Sep­tem­ber with a Roche study in neoad­ju­vant-stage triple-neg­a­tive breast can­cer.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.